Between 2012 and 2019, researchers developed and identified a series of FTO inhibitors, such as rhein, MO-I-500, methylclofenac (MA), fluorescein, 2-hydroxyglutaric acid (R-2HG), FB23, and FB23-2, which showed significant anti-tumor effects in vitro and in vivo. This evidence concerns the gene FTO and neoplasm.